# US 2021/0332092 A1 · Articles comprising a silk polypeptide for antigen delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332092 A1
- Document ID: US20210332092A1
- Status: Published application
- Kind: A1
- Application number: 17/245,818
- Filed: 2021-04-30
- Published: 2021-10-28
- Earliest claimed: 2016-06-22
- Assignees: Amsilk GmbH; Ludwig-Maximilians-Universitat Munchen; Universitat Bayreuth
- Applicants: AMSILK GmbH; Ludwig-Maximilians-Universitat Munchen; Universitat Bayreuth
- Inventors: Lin ROMER; Ute SLOTTA; Julia ENGERT; Gerhard WINTER; Matthias LUCKE; Thomas SCHEIBEL
- Web page: https://patentgrep.com/patent/US20210332092A1

## CPC

- C07K 14/43518: {from spiders}
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61P 35/00: Antineoplastic agents
- C07K 14/43586: {from silkworms}
- C12N 15/62: DNA sequences coding for fusion proteins
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/6031: {Proteins}
- A61K 2039/627: {characterised by the linker}
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C07K 2319/50: containing protease site
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a polypeptide comprising a silk polypeptide and an antigen. Further, the present invention relates to an article comprising the polypeptide. Furthermore, the present invention relates to a pharmaceutical composition comprising the article. In addition, the present invention relates to the article or pharmaceutical composition for use as a pharmaceutical, for inducing an immune response and/or for use in a prophylactic and/or therapeutic treatment of a disease.

## Claims

### Claim at position 1

-15. (canceled)

### Claim 16

A method for inducing an immune response in a subject comprising the steps of:
(i) providing a polypeptide comprising
(a) a silk polypeptide,
(b) an antigen, and
(c) an enzymatically cleavable linker,
wherein the antigen is connected to the silk polypeptide via the enzymatically cleavable linker, and
(ii) administering the polypeptide provided in (i) to a subject in need thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the enzymatically cleavable linker is a protease cleavable linker.

### Claim 18 (depends on 17)

The method of claim 17, wherein the protease cleavable linker is a cathepsin cleavable linker.

### Claim 19 (depends on 18)

The method of claim 18, wherein the cathepsin cleavable linker is a cathepsin S cleavable linker.

### Claim 20 (depends on 18)

The method of claim 18, wherein the cathepsin cleavable linker is a cathepsin B cleavable linker.

### Claim 21 (depends on 16)

The method of claim 16, wherein the polypeptide is comprised in a particle.

### Claim 22 (depends on 16)

The method of claim 16, wherein the polypeptide is comprised in a pharmaceutical composition which is free of any adjuvant.

### Claim 23 (depends on 21)

The method of claim 21, wherein the particle comprising the polypeptide is comprised in a pharmaceutical composition which is free of any adjuvant.

### Claim 24 (depends on 16)

The method of claim 16, wherein the immune response is induced against the antigen in the patient.

### Claim 25 (depends on 16)

The method of claim 16, wherein the immune response is induced against cancer, an infectious disease, or an autoimmune disease.

### Claim 26 (depends on 16)

The method of claim 16, wherein the induction of the immune response results in the immunization or vaccination of the patient.

### Claim 27

A method for vaccinating a subject comprising the steps of:
(i) providing a polypeptide comprising
(a) a silk polypeptide,
(b) an antigen, and
(c) an enzymatically cleavable linker,
wherein the antigen is connected to the silk polypeptide via the enzymatically cleavable linker, and
(ii) administering the polypeptide provided in (i) to a subject in need thereof.

### Claim 28 (depends on 27)

The method of claim 27, wherein the polypeptide is comprised in a particle.

### Claim 29

A method for stimulating, priming, and/or expanding T cells in a subject comprising the steps of:
(i) providing a polypeptide comprising
(a) a silk polypeptide,
(b) an antigen, and
(c) an enzymatically cleavable linker,
wherein the antigen is connected to the silk polypeptide via the enzymatically cleavable linker, and
(ii) administering the polypeptide provided in (i) to a subject in need thereof.

### Claim 30 (depends on 29)

The method of claim 29, wherein the polypeptide is comprised in a particle.
